The Real-World Efficacy and Safety of Anlotinib Treatment for Advanced Non-Small Cell Lung Cancer

被引：0
|
作者：
Wang, F. [1 ]
Jin, F. [1 ]
Wang, S. [1 ]
Zhu, Y. [1 ]
机构：
[1] Peking Univ, Dept Oncol, Shenzhen Hosp, Shenzhen, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P86.04
引用
收藏
页码：S673 / S673
页数：1
相关论文
共 50 条
  • [21] Salvage treatment with anlotinib for advanced non-small cell lung cancer
    Wu, Di
    Nie, Jun
    Dai, Ling
    Hu, Weiheng
    Zhang, Jie
    Chen, Xiaoling
    Ma, Xiangjuan
    Tian, Guangming
    Han, Jindi
    Han, Sen
    Long, Jieran
    Wang, Yang
    Zhang, Ziran
    Fang, Jian
    [J]. THORACIC CANCER, 2019, 10 (07) : 1590 - 1596
  • [22] Immune checkpoint inhibitors in advanced non-small cell lung cancer: Real-world survival and safety
    Tang, Monica
    Lee, Chee
    Lewis, Craig
    Boyer, Michael
    Brown, Bernadette
    Schaffer, Andrea
    Pearson, Sallie-Anne
    Simes, Robert
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 30 - 31
  • [23] Efficacy and Safety Evaluations of Anlotinib in Patients with Advanced Non-small Cell Lung Cancer Treated with Bevacizumab
    Jiang, F.
    Li, J.
    Kong, X.
    Qu, H.
    Sun, P.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S436 - S436
  • [24] Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study
    Ma, Ke
    Guo, Qianqian
    Li, Xingya
    [J]. BMC PULMONARY MEDICINE, 2023, 23 (01)
  • [25] Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study
    Ke Ma
    Qianqian Guo
    Xingya Li
    [J]. BMC Pulmonary Medicine, 23
  • [26] Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients
    Lee, Po-Hsin
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Huang, Yen-Hsiang
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    Chang, Gee-Chen
    [J]. ANTI-CANCER DRUGS, 2021, 32 (10) : 1099 - 1104
  • [27] Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
    Jiang, Fenge
    Li, Junxia
    Kong, Xiangshuo
    Sun, Ping
    Qu, Huajun
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [28] Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer
    Xuetian Gao
    Ling Peng
    Li Zhang
    Kai Huang
    Cuihua Yi
    Bei Li
    Xue Meng
    Jisheng Li
    [J]. Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2661 - 2671
  • [29] Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer
    Gao, Xuetian
    Peng, Ling
    Zhang, Li
    Huang, Kai
    Yi, Cuihua
    Li, Bei
    Meng, Xue
    Li, Jisheng
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (10) : 2661 - 2671
  • [30] Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study
    Jiang, Hong-Tao
    Li, Wei
    Zhang, Biao
    Gong, Qiang
    Qie, Hai-Ling
    [J]. INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 7625 - 7637
12345